DBD Ex-Dividend Reminder - 5/15/13

Looking at the universe of stocks we cover at Dividend Channel, on 5/15/13, Diebold, Inc. (DBD) will trade ex-dividend, for its quarterly dividend of $0.2875, payable on 6/7/13. As a percentage of DBD's recent stock price of $30.54, this dividend works out to approximately 0.94%, so look for shares of Diebold, Inc. to trade 0.94% lower — all else being equal — when DBD shares open for trading on 5/15/13.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for DBD, showing historical dividends prior to the most recent $0.2875 declared by Diebold, Inc.:

DBD+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from DBD is likely to continue, and whether the current estimated yield of 3.77% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of DBD shares, versus its 200 day moving average:

Diebold, Inc. 200 Day Moving Average Chart

Looking at the chart above, DBD's low point in its 52 week range is $27.59 per share, with $38.49 as the 52 week high point — that compares with a last trade of $30.53.

According to the ETF Finder at ETF Channel, DBD makes up 1.12% of the SPDR S&P Dividend ETF ( SDY) which is trading lower by about 0.2% on the day Monday.

In Monday trading, Diebold, Inc. shares are currently down about 0.5% on the day.

null

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says